Alvotech Sa Share Price (NASDAQ: ALVO)

$8.07

▲

0.02

(0.25%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Alvotech Sa Stock chart to analyse performance

Alvotech Sa stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$7.96
Today's High:$8.07
$8.07
1.36%
Downside
Day's Volatility :1.36%
Upside
0.0%
52 Weeks Low:$7.35
52 Weeks High:$13.70
$8.07
8.92%
Downside
52 Weeks Volatility :46.35%
Upside
41.09%

Alvotech Sa Stock Returns

Period	Alvotech Sa	Sector (Health Care)	Index (Russel 2000)
3 Months	-28.22%	3.6%	0.0%
6 Months	-27.48%	-7.7%	0.0%
1 Year	-29.07%	-12.6%	0.0%
3 Years	4.41%	9.5%	-4.7%

Alvotech Sa Key Stats

Check Alvotech Sa key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.05
Open	$8.04
Today's High	$8.07
Today's Low	$7.96
Market Capitalization	$2.5B
Today's Volume	$229.9K
52 Week High	$13.7
52 Week Low	$7.35
Revenue TTM	$562.5M
EBITDA	$74.8M
Earnings Per Share (EPS)	$0.23
PE Ratio	35.0
Profit Margin	11.26%
Quarterly Earnings Growth YOY	-0.58%
Return On Equity TTM	0.0%

Stock Returns calculator for Alvotech Sa Stock including INR - Dollar returns

The Alvotech Sa stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Alvotech Sa investment value today

Current value as on today

₹76,385

Returns

₹23,615

(-23.61%)

Returns from Alvotech Sa Stock

₹28,899 (-28.9%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Alvotech Sa Stock

32%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Alvotech Sa Stock from India on INDmoney has increased by 32% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Alvotech Sa Stock

Rating

Trend

Buy

72%Buy

27%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Alvotech Sa(by analysts ranked 0 to 5 stars)

Alvotech Sa Share Price Target

What analysts predicted

Upside of 116.85%

Target:

$17.50

Current:

$8.07

Alvotech Sa share price target is $17.50, a slight Upside of 116.85% compared to current price of $8.07 as per analysts' prediction.

Alvotech Sa Stock Insights

Price Movement
In the last 3 months, ALVO stock has moved down by -29.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 132.76M → 173.23M (in $), with an average increase of 23.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 109.68M → 32.03M (in $), with an average decrease of 70.8% per quarter
ALVO vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 41.0%
ALVO vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 35.1% return, outperforming this stock by 44.2%
Price to Sales
ForALVO every $1 of sales, investors are willing to pay $4.1, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Alvotech Sa Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$31.9M	-
Net Income	$-209.9M	-
Net Profit Margin	-657.55%	-

	FY20	Y/Y Change
Revenue	$66.6M	↑ 108.71%
Net Income	$-170.0M	↓ 18.98%
Net Profit Margin	-255.26%	↑ 402.29%

	FY21	Y/Y Change
Revenue	$36.8M	↓ 44.8%
Net Income	$-101.5M	↓ 40.31%
Net Profit Margin	-276.04%	↓ 20.78%

	FY22	Y/Y Change
Revenue	$83.0M	↑ 125.79%
Net Income	$-513.6M	↑ 405.97%
Net Profit Margin	-618.55%	↓ 342.51%

	FY23	Y/Y Change
Revenue	$91.4M	↑ 10.12%
Net Income	$-551.7M	↑ 7.43%
Net Profit Margin	-603.42%	↑ 15.13%

	FY24	Y/Y Change
Revenue	$489.7M	↑ 435.56%
Net Income	$-231.9M	↓ 57.98%
Net Profit Margin	-47.35%	↑ 556.07%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$12.4M	↓ 76.72%
Net Income	$-218.7M	↓ 20.91%
Net Profit Margin	-1.8K%	↓ 1241.7%

	Q2 FY24	Q/Q Change
Revenue	$198.8M	↑ 1498.98%
Net Income	$65.2M	↓ 129.82%
Net Profit Margin	32.82%	↑ 1792.51%

	Q3 FY24	Q/Q Change
Revenue	$102.9M	↓ 48.23%
Net Income	$-11.4M	↓ 117.47%
Net Profit Margin	-11.07%	↓ 43.89%

	Q4 FY24	Q/Q Change
Revenue	$151.2M	↑ 46.96%
Net Income	$-67.0M	↑ 487.79%
Net Profit Margin	-44.29%	↓ 33.22%

	Q1 FY25	Q/Q Change
Revenue	$132.8M	↓ 12.2%
Net Income	$109.7M	↓ 263.78%
Net Profit Margin	82.61%	↑ 126.9%

	Q2 FY25	Q/Q Change
Revenue	$173.2M	↑ 30.49%
Net Income	$32.0M	↓ 70.79%
Net Profit Margin	18.49%	↓ 64.12%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$31.9M	-

	FY20	Y/Y Change
Profit	$66.6M	↑ 108.71%

	FY21	Y/Y Change
Profit	$36.8M	↓ 44.8%

	FY22	Y/Y Change
Profit	$18.9M	↓ 48.51%

	FY23	Y/Y Change
Profit	$-69.4M	↓ 466.65%

	FY24	Y/Y Change
Profit	$304.4M	↓ 538.44%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-7.5M	↑ 148.5%

	Q2 FY24	Q/Q Change
Profit	$153.5M	↓ 2139.9%

	Q3 FY24	Q/Q Change
Profit	$63.1M	↓ 58.92%

	Q4 FY24	Q/Q Change
Profit	$70.9M	↑ 12.37%

	Q1 FY25	Q/Q Change
Profit	$67.3M	↓ 5.02%

	Q2 FY25	Q/Q Change
Profit	$99.4M	↑ 47.68%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-88.5M	-
Investing Cash Flow	$-12.9M	-
Financing Cash Flow	$116.4M	-

	FY20	Y/Y Change
Operating Cash Flow	$-74.3M	↓ 16.1%
Investing Cash Flow	$-16.9M	↑ 31.28%
Financing Cash Flow	$55.4M	↓ 52.39%

	FY21	Y/Y Change
Operating Cash Flow	$-228.2M	↑ 207.11%
Investing Cash Flow	$-40.6M	↑ 140.39%
Financing Cash Flow	$254.8M	↑ 359.97%

	FY22	Y/Y Change
Operating Cash Flow	$-312.4M	↑ 36.91%
Investing Cash Flow	$-63.5M	↑ 56.37%
Financing Cash Flow	$424.9M	↑ 66.74%

	FY23	Y/Y Change
Operating Cash Flow	$-312.2M	↓ 0.07%
Investing Cash Flow	$-46.3M	↓ 27.07%
Financing Cash Flow	$301.3M	↓ 29.09%

	FY24	Y/Y Change
Operating Cash Flow	$-236.8M	↓ 24.13%
Investing Cash Flow	$-18.9M	↓ 59.28%
Financing Cash Flow	$297.3M	↓ 1.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-75.4M	↑ 12.27%
Investing Cash Flow	$-3.5M	↓ 66.74%
Financing Cash Flow	$133.2M	↑ 544.6%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-50.6M	↓ 32.9%
Investing Cash Flow	$-7.1M	↑ 103.71%
Financing Cash Flow	$4.0M	↓ 97.0%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-71.6M	↑ 41.59%
Investing Cash Flow	$22.8M	↓ 420.96%
Financing Cash Flow	$155.8M	↑ 3793.75%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-39.2M	↓ 45.28%
Investing Cash Flow	$-31.1M	↓ 236.47%
Financing Cash Flow	$4.3M	↓ 97.24%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$12.5M	↓ 132.01%
Investing Cash Flow	$-20.4M	↓ 34.32%
Financing Cash Flow	$-5.8M	↓ 235.92%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$55.7M	↑ 344.19%
Investing Cash Flow	$-28.6M	↑ 40.25%
Financing Cash Flow	$83.1M	↓ 1523.99%

Alvotech Sa Technicals Summary

Sell

Neutral

Buy

Alvotech Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Alvotech Sa Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alvotech Sa	-11.15%	-27.48%	-29.07%	4.41%	-28.06%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alvotech Sa	35.0	35.0	NA	0.35	0.0	0.03	NA	-0.56
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alvotech Sa	Buy	$2.5B	-28.06%	35.0	11.26%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Alvotech Sa

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Organization	Alvotech Sa
Employees	1012
CEO	Mr. Robert Wessman
Industry	Services

Key Management of Alvotech Sa

Name	Title
Mr. Robert Wessman	CEO, Founder & Executive Chairman
Ms. Linda Jonsdottir	Chief Financial Officer
Mr. Giedrius Zunda	Chief Technical Officer
Mr. Joseph E. McClellan	Chief Scientific Officer
Mr. Benedikt Stefansson	VP of Investor Relations and Global Communications
Ms. Tanya Zharov	General Counsel
Ms. Jenny Sif Steingrimsdottir	Vice President of People & Culture
Mr. Anil Okay	Chief Commercial Officer
Mr. Anthony M. Maffia III	Chief Regulatory Affairs Officer
Mr. Uri Hillel	Chief Quality Officer

Important FAQs about investing in ALVO Stock from India :

What is Alvotech Sa share price today?

Alvotech Sa share price today is $8.07 as on August 30, 2025 at 1:29 am IST at the close of the market. Alvotech Sa share today touched a day high of $8.07 and a low of $7.96.

What is the 52 week high and 52 week low for Alvotech Sa share?

Alvotech Sa share touched a 52 week high of $13.70 and a 52 week low of $7.35. Alvotech Sa stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $8.07, lower by 41.09% versus the 52 week high.

How to invest in Alvotech Sa Stock (ALVO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Alvotech Sa on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alvotech Sa Shares that will get you 0.1859 shares as per Alvotech Sa share price of $8.07 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Alvotech Sa Stock (ALVO) from India?

Indian investors can start investing in Alvotech Sa (ALVO) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Alvotech Sa stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Alvotech Sa share’s latest price of $8.07 as on August 30, 2025 at 1:29 am IST, you will get 1.2392 shares of Alvotech Sa. Learn more about fractional shares .

What are the returns that Alvotech Sa has given to Indian investors in the last 5 years?

Alvotech Sa stock has given -28.06% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?